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Abstract
Chronic wasting disease (CWD) is a prion disease affecting captive and free-ranging cervids (e.g. deer, elk, and moose). The
mechanisms of CWD transmission are poorly understood, though bodily fluids are thought to play an important role. Here
we report the presence of infectious prions in the urine and saliva of deer with chronic wasting disease (CWD). Prion
infectivity was detected by bioassay of concentrated, dialyzed urine and saliva in transgenic mice expressing the cervid PrP
gene (Tg[CerPrP] mice). In addition, PrP
CWD was detected in pooled and concentrated urine by protein misfolding cyclic
amplification (PMCA). The concentration of abnormal prion protein in bodily fluids was very low, as indicated by:
undetectable PrP
CWD levels by traditional assays (western blot, ELISA) and prolonged incubation periods and incomplete
TSE attack rates in inoculated Tg(CerPrP) mice (373
63days in 2 of 9 urine-inoculated mice and 342
6109 days in 8 of 9 saliva-
inoculated mice). These findings help extend our understanding of CWD prion shedding and transmission and portend the
detection of infectious prions in body fluids in other prion infections.
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Introduction
Chronic wasting disease (CWD) is an efficiently transmitted
prion disease of cervids (e.g. deer, elk, and moose) and is the only
prion disease affecting free-ranging, non-domestic animals. The
origins of CWD are uncertain, but the disease has been present in
wild cervid populations of northern Colorado and southern
Wyoming for at least 40 years [1,2]. Since its discovery, CWD
has been identified in captive and free-ranging cervids in 15 states,
2 Canadian provinces, and Korea [3]. As surveillance efforts have
intensified, CWD has been detected in areas previously thought to
be free of infection, including recent discoveries in West Virginia,
New York, and Michigan. The prevalence of CWD varies across
North America, but can be as high as 30% in some areas of
Colorado [4].
The mechanisms of CWD transmission are not well understood,
although there is evidence that infection is transmitted horizontally
and can be acquired from environmental sources [5,6], which
underlies the assumption that shedding of infectious prions must
be significant. With the expanded recognition of the disease across
the continental United States, it is also likely that substantial
human exposure has occurred. Nevertheless, because of an
apparently strong species barrier [7] and the as yet incompletely
understood natural routes and kinetics of CWD transmission, the
magnitude and consequence of this exposure remain speculative.
Infectious CWD prions have been detected in saliva and blood,
e.g. ‘‘prionsialia’’ and ‘‘prionemia,’’ suggesting a role for specific
body fluids in transmission and dissemination [6]. In these
bioassay studies in deer, infectivity in urine and feces could not
be demonstrated, seemingly at odds with indirect evidence for
environmental persistence of CWD prions [5,8]. In that the
presence of prions in body fluids, once thought not to occur, now
has impact in understanding of prion transmission and biocontain-
ment, we have continued and extended our investigation of this
subject with the present studies.
Materials and Methods
Cervid sources
Samples of urine and saliva were collected at terminal disease
from five experimentally infected white-tailed deer. Deer in this
cohort had been inoculated intracranially with brain, intravenous-
ly with blood, or orally with saliva from CWD-infected deer. All
source deer were in the terminal stages of CWD infection, and
demonstrated moderate to severe neurologic signs, paradoxical
polyphagia with declining body condition, polydypsia and
polyuria, and were confirmed CWD+ by western blot and
immunohistochemistry, as previously described [6]. Histopatho-
logic examination revealed mild nephritis in all the source deer. In
some cases, these changes were age related, while in a single case
there was appreciable evidence of pyelonephritis. Four of five the
deer were homozygous for glycine at amino acid 96 of the cervid
prion gene, while one deer was heterozygous at that location, with
alleles encoding for both glycine and serine [6].
Cervid PrP transgenic mice
Tg[CerPrP] line 1536 (tg1536) mice were generated in the
Telling laboratory at the University of Kentucky [9]. All mice were
screened at weaning for the presence of the [CerPrP] construct by
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PrP
CWD at the completion of bioassay studies were rescreened to
reconfirm the presence of cervid PrP gene. Animals were treated
according to Colorado State University guidelines.
Study samples and preparation
A 1% w/v homogenate of brain from a single CWD-positive
mule deer (provided by Dr. Michael Miller, Colorado Division of
Wildlife) was used as the positive control material. A 1% w/v
homogenate of brain from a single CWD-negative white-tail deer
from outside the CWD-endemic zone was used as a negative
control and was provided by David Osborne, University of
Georgia. Urine and saliva samples were collected from five
symptomatic whitetail deer as described above.
Spiked positive and negative control samples consisted of 1%
homogenates of positive or negative deer brain prepared using
10 ml of negative control saliva or urine as diluent. For the study
groups, 10 mls of either urine or saliva were collected from each of
five symptomatic deer, 50 ml total volume, and homogenized. All
urine and saliva homogenates were then prepared for bioassay by
lyophilization followed by resuspension in 0.1 volumes of
phosphate-buffered saline (PBS) (e.g. a 10-fold concentration)
and dialyzed against 2000 volumes of PBS to return the sample to
isotonicity.
Mouse bioassays
Mice were anesthetized with ketamine and xylazine and
inoculated intracerebrally into the left parietal lobe with 30 mlo f
inoculum. Incubation time was defined as the number of days
from inoculation to the onset of clinical neurological signs
consistent with a TSE [10]. Animals were euthanized when either
a symptomatic TSE or signs of distress were evident. Brains were
harvested at necropsy and divided longitudinally, with one half
prepared for evaluation by western blotting and PMCA, while the
remaining half was fixed in 10% neutral-buffered formalin for
histopathology and immunohistochemistry.
Western blotting (WB)
Brain tissue was initially prepared as a 10% (w/v) suspension in
homogenization buffer (150 mM NaCl, 5 mM EDTA, and 1%[v/
v] triton-X 100 in PBS). Eleven ml of sample homogenate were
mixed with 7 ml of sample buffer (0.1% [v/v] triton-X 100 and
4%(w/v) SDS in PBS) and digested with 2 ml proteinase-K at
500 mg/ml (final concentration: 50 mg/ml) for 209 at 37uC followed
by 109 at 45uC. Seven mlo f4 6running buffer were then added to
the sample, followed by denaturation for 59 at 95uC. Twenty mlo f
this preparation were run on a pre-cast 12% SDS-PAGE gel
(Invitrogen) in a Bio-Rad electrophoresis apparatus for 2 hours at
110 mV. Samples were then transferred to a PVDF membrane for
1 hour at 110 mV in a Bio-Rad transfer apparatus. PVDF
membranes were subsequently blocked for 1 hour in 5%(w/v)
powdered milk in TBST, followed by application of the primary
antibody, BAR224-HRP, diluted 1:20,000 in 5% powdered milk in
TBST, for 1 hour. Following washing, immunoreactivity was
detected using an enhanced chemiluminescent detection system
(ECL-plus, Amersham Biosciences) in an LAS 3000
TM imaging
system. (Fuji Photo Film, Fuji Inc, Valhalla, NY)
Histopathology and Immunohistochemistry (IHC)
Cervid renal tissues and tg1536 neural tissues were fixed in
formalin overnight, treated with 88% formic acid for one hour,
washed in tap water for two hours, and then stored in 60% ethanol
prior to paraffinization. Paraffin-embedded tissue sections (6 mm)
were mounted onto positively charged glass slides, deparaffinized,
and rehydrated through graded ethanol. Tissues were subjected to
Heat Induced Epitope Retrieval (HIER) using an automated
antigen-retrieval system (Retriever
TM) and a proprietary buffer
solution (DakoCytomation Target Retrieval Solution, DAKO,
Hamburg, Germany). Tissues were then stained with an
automated immunostainer, using PrP monoclonal antibody
BAR-224 conjugated to HRP as the primary antibody (1:250
final dilution). Detection was completed using HRP-mediated
hydrogen peroxide immunostaining (AEC+, DAKO), with
haematoxylin as a counterstain.
Protein Misfolding Cyclic Amplification (PMCA)
Source inocula as well as mice negative for PrP
CWD by both WB
and IHC were further analyzed by PMCA. The amplification
protocol, described below, was similar to those described by Soto
and colleagues [11,12]. Normal brain homogenate (NBH), the
substrate for prion conversion in vitro, was prepared in a room that
had not previously been used for prion research as follows: naı ¨ve
tg1536 mice were euthanized intraperitoneally with 15 mg of
sodium pentobarbital and perfused with 25 ml of 5 mM EDTA in
PBS via intracardiac catheterization. The calvarium was removed
and the entire brain excised and placed on ice. Brain homogenate
was then prepared at a 10% (w/v) solution in PMCA buffer (1%
triton-X 100 [v/v], 5 mM EDTA, 150 mM NaCl, and 0.5%
saponin [w/v] in PBS adjusted to a pH of 7.2) with the addition of
Complete Protease Inhibitors (Roche Pharmaceuticals, Indiana-
polis, IN) in a dounce homogenizer. Homogenates were then
centrifuged for 1 minute at 2000 rpm to remove bulk brain
material, and the supernatant frozen in single-experiment aliquots
at 270uC in a ‘‘prion-free’’ room until use in PMCA.
Experimental handling protocols were identical to protocols
commonly used for PCR: NBH was added to a plate in a room
not previously used for prion research and then transferred to a
room used exclusively for prion research, where samples were
added in a biosafety hood prior to sonication. Twenty-five mlo f
either source inocula or WB and IHC negative brain homogenate
was added to 25 ml of NBH in individual wells of a 96 well PCR
plate (USA Scientific, Ocala, FL), placed in an ultrasonic processor
(Misonix, Farmingdale, NY) and incubated at 37uC. Samples were
sonicated for 40 s at power setting 7.0, followed by 30 minutes of
incubation. Ninety six cycles of sonication were preformed over
48 hours, with a 25 ml aliquot transferred to a fresh NBH
preparation for serial amplification. Following three rounds of
amplification, samples were evaluated by western blotting, as
described above, for the presence of PrP
CWD.
Results
To investigate whether urine may play a role in natural CWD
transmission, and to confirm the presence of PrP
CWD in saliva, we
pooled and concentrated urine or saliva from five terminally
infected CWD+ deer and inoculated two groups of tg1536 mice.
Following inoculation, mice were monitored for clinical signs of
prion infection and were euthanized when terminal disease was
apparent. Central nervous system tissues were evaluated for
PrP
CWD using western blotting (WB), immunohistochemistry
(IHC) and, when negative by conventional assays, protein
misfolding cyclic amplification (PMCA).
In a group of 9 mice inoculated with lyophilized urine, 2
animals developed neurologic disease consistent with a TSE
(Table 1), including ataxia, a slow, lumbering gait, and poor thrift,
at 370 and 376 days post-inoculation (dpi). Eight out of 9 mice
inoculated with prepared saliva likewise developed signs of TSE at
CWD Prions in Urine and Saliva
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with CWD+ brain spiked into either urine or saliva, developed
disease before 370 dpi (235+/291 dpi), while none of the mice in
either negative control group, inoculated with either urine or
saliva spiked with negative brain homogenate, demonstrated
clinical evidence of a TSE after .640 days.
WB and IHC results
Brains of all mice demonstrating terminal neurologic disease,
including 2 of 9 inoculated with urine and 8 of 9 inoculated with
saliva, had evidence of protease-resistant prion protein by both
WB and IHC. PrP
CWD was absent by both WB and IHC in mice
not displaying clinical disease, including those in negative control
groups.
Immunohistochemistry demonstrated widely distributed, florid
PrP
CWD plaques, with no apparent relationship between deposi-
tion pattern, lesion severity, and source inoculum (Figure 1). In
cases with the least severe pathology, however, cortical lesions
predominated; with increasing neuropathology, lesions were
further distributed within the hippocampus, midbrain, and
cerebellum.
In western blotting, PrP
CWD proteinase K-resistant glycoforms
spanned 21–27 kD. In all cases, the dominant PrP
CWD glycoform
was the di-glycosylated band, followed by mono- and non-
glycosylated isoforms (Figure 2).
To identify potential pathological mechanisms for prionuria,
histopathologic examination of donor renal tissues was also
performed. Microscopic evaluation of H&E stained kidney
sections from each of the donor deer revealed minimal histologic
disease in 4 of the 5 animals. Lesions in these animals were
characterized by the combination of minimal proliferative
glomerular disease and mild interstitial fibrosis and lymphocytic
inflammation (Figure 3A and B). In these animals, there was no
appreciable histologic evidence of proteinuria or pyelonephritis. In
the fifth animal, more significant renal pathology was detected. In
this animal, there was a combination of mild, chronic, lymphocytic
glomerulonephritis, which was similar to the previous 4 animals,
and a moderately severe, chronic, lymphocytic interstitial nephritis
with light microscopic evidence of renal protein loss (‘‘tubular
proteinosis’’). (Figures 3C and D).
PMCA
Concentrated samples used for mouse inoculation were assayed
for PrP
CWD by serial PMCA (sPMCA) over three rounds of
amplification. In our experience, three rounds of amplification
permits an approximate 4000-fold increase in sensitivity as
compared to traditional western blotting detection, while avoiding
Table 1. Western Blot (WB), immunohistochemistry (IHC), and
protein-misfolding cyclic amplification results and incubation
periods of Tg[CerPrP] mouse bioassay.
Mouse Bioassay
Inoculum WB+ IHC+ PMCA+ Incubation Period
(+) Control 18/18 18/18 N.A. 235+/291d
Urine 2/9 2/9 1/7 373+/23d
Saliva 8/9 8/9 0/1 342+/2109d
(2) Control 0/18 0/18 0/18 .640d
Numerators indicate the number of animals testing positive by a particular
assay, while denominators designate the total number tested. PMCA analysis
was reserved for mice testing negative by traditional assays. Incubation periods
indicate the survival times in days post inoculation +/2 one standard deviation.
N.A. - not assayed.
doi:10.1371/journal.pone.0004848.t001
Figure 1. Spongiform degeneration and PrP
CWD identified by histopathology and immunohistochemistry. Vacuolated neurons and
spongiform degeneration of the neuropil characteristic of a TSE is evident on H&E staining, with the colocalization of PrP
CWD specific immunostaining
of florid plaques in the cortices of mice inoculated with positive control inoculum and concentrated urine and saliva from CWD-infected cervids.
Negative control mice showed no evidence of spongiform degeneration or PrP
CWD immunostaining. HRP-conjugated BAR-224 was used as a primary
antibody. (Measure bar, 50 mm).
doi:10.1371/journal.pone.0004848.g001
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formed protease-resistant PrP, thereby maintaining 100% speci-
ficity [13]. In three independent experiments, PrP
CWD was
identified in lyophilized urine homogenate from CWD+ deer.
(Figure 4A) PrP
CWD was also found in both positive control
inocula after the initial round of amplification, while PrP
CWD was
not detected in either saliva or negative control preparations.
To increase detection sensitivity in bioassay experiments, brains
from all mice that tested negative for PrP
CWD by WB and IHC,
including negative controls, were re-evaluated by sPMCA. The
brain from one WB2 and IHC-negative mouse that had been
inoculated with urine from a CWD+ deer and expired at 582 dpi
amplified PrP
CWD in three independent PMCA experiments
(Figure 4B). No mice in either of the negative control groups were
positive using this assay.
Discussion
The salient feature of chronic wasting disease is its facile
transmission among its host species. Until recently, little was
known regarding the mechanisms of this efficient transmissibility,
however, we have previously demonstrated infectious prions in the
saliva and blood of infected deer [6]. By using intracerebral
inoculation of concentrated urine in cervid PrP transgenic mice,
we report the presence of infectious prions in urine from CWD-
infected cervids, and confirm the phenomenon of prionsialia in
these animals. The identification of CWD prions in bodily fluids
described in the current report could portend infectivity in
secretions and excretions in other prion diseases.
Figure 2. Western Blot detection of PrP
CWD in urine and saliva-
inoculated mice. Western blotting analysis of control and test mice,
demonstrating PrP
CWD in positive control mice (lanes 1 and 2), as well as
urine (lanes 3 and 4) and saliva (lanes 5 and 6) inoculated mice.
Protease-resistant prions were not detected in negative control mice
(lanes 7 and 8). Flanking lanes represent undigested PrP
C.
doi:10.1371/journal.pone.0004848.g002
Figure 3. Histopathologic evaluation of renal tissues from donor cervids. (A) Minimal, chronic and proliferative glomerular disease and (B)
mild interstitial fibrosis and lymphocytic infiltration were observed in 4 out of 5 donor deer. The remaining deer showed evidence of mild
lymphocytic glomerulonephritis (C) as well as ‘‘tubular proteinosis.’’ (D, arrows).
doi:10.1371/journal.pone.0004848.g003
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in cervid bioassays was unable to identify infectious prions in the
urine of CWD+ deer [6]. This result could have been due to
necessarily limited observation period possible in those studies (18
months), or variations in source and recipient genotype [14,15],
route of inoculation [16], or the sensitivity of traditional PrP
CWD
detection assays [17,18]. The mule deer providing inoculum pools
in prior studies were of an unreported genotype; the majority of
the recipient deer were homozygous for glycine at residue 96,
although a single animal was heterozygous; sharing both G96 and
S96 alleles [6]. Likewise, the inocula used in the present study were
pooled from sources heterogeneous at codon 96 of the cervid prion
gene. Transgenic mice used in bioassay studies, on the other hand,
were uniformly homogenous for a glycine residue at this position
[9], a polymorphism which is reported to be overrepresented in
CWD-infected deer [19]. As a result, it is possible that the
genotypic background of either source or subject animals may
have been a factor in susceptibility, though we are at present
unable to draw any concrete conclusions regarding this relation-
ship. While mouse genotype may have played a role in the
outcome, it is also probable that cervid PrP transgenic mouse
bioassay simply represents a more sensitive detection system for
prions in excreta. Intracranial inoculation, reportedly a more
sensitive route of prion exposure [16,20], is more easily performed
in mouse bioassay, a model which also permits extended
incubation periods and inclusion of a greater number of test
animals.
While our findings point to urine as an additional vehicle for
CWD transmission, only 2 of 9 inoculated tg1536 mice were
confirmed WB/IHC-positive for prion infection, with a third
PrP
CWD+ animal later identified by PMCA. This contrasts with 8
of 9 positive mice receiving saliva and infers a much lower
concentration of prion infectivity in urine. The wide range of
survival times in inoculated mice suggests relatively low levels of
infectious prions and/or uneven distribution of infectious PrP
moieties in the inocula [21]. Differing [CerPrP] zygosity in tg1536
mice (homozygous vs. hemizygous) may also have played a role in
this variation.
Using sPMCA, PrP
CWD was repeatedly identified in test urine
and spiked urine and saliva used as positive control, but was not
detected in test saliva after three rounds of amplification. The
reasons for our inability to identify PrP
CWD in saliva – given the
definitive bioassay findings – remain unknown, and we propose
the presence of as-yet unidentified inhibitors such as mucin or
salivary proteases which are thought to negatively affect other in
vitro assays [22,23].
The finding of PrP
CWD in urine and saliva calls for the
identification of the pathological processes and cellular associa-
tions of the prion protein involved in shedding. Previous studies
have related renal pathology to prionuria [24,25], a finding which
corresponds to our identification of mild to moderate nephritis in
those deer providing samples for the current study. It is plausible
that renal pathology contributed to prionuria in each of these
animals; as samples were pooled, however, we cannot identify
specific animals in which it may have been occurring, nor can we
accurately estimate the relative level of prionuria occurring in each
donor as ultrastructural studies were not performed [26]. While we
have not yet identified pathologic prions in renal source tissues
[Unpublished data], protease-resistant PrP
CWD has been identified
by immunostaining in renal tissue of prion-infected deer [27],
sheep [28], hamsters and most intriguingly humans [29],
foreshadowing the potential for prionuria in other transmissible
spongiform encephalopathies. We continue to examine tissues
from CWD+ deer in an effort to determine the pathogenesis and
kinetics of CWD prion excretion and shedding.
Evidence for excretion and shedding of infectious prions is also
accumulating in the scrapie system. PrP
C-converting activity has
been identified by sPMCA in the urine of scrapie-infected sheep,
hamsters and mice [21,30,31,32]. Prion infectivity has also been
demonstrated in the feces of hamsters orally infected with scrapie
[33]. Other studies point to infectious prions in the milk of scrapie-
infected ewes [34,35]. As noted above, it remains unknown
whether other prion diseases (e.g. Kuru, BSE, CJD, TME) may be
transmitted by bodily fluids or excreta other than blood.
Additional studies examining feces, milk, and other body fluids
are therefore necessary in CWD and other prion diseases, studies
currently underway in our laboratory.
As CWD transmission may model communicability of other
TSE’s, the transmissible nature of prion diseases may serve as a
model for other protein-misfolding diseases. For example, feces,
but not urine, from both mice and cheetahs affected with systemic
amyloidosis A (SAA) was recently shown to induce SAA in a
mouse model, although negative controls were not available in
those studies [36]. In light of the prionuria detected in CWD and
in models of scrapie, further investigations of infectivity in body
fluids in other protein folding diseases may be warranted in the
event that prion diseases are not the only infectious proteinopa-
thies.
In summary, we confirm prionsialia in CWD-affected deer by
bioassay in cervidized mice and demonstrate for the first time
infectious prions in the urine of these cervids by both bioassay and
sPMCA. We are currently evaluating urine and saliva from
individual animals in hopes of identifying predisposing factors,
such as genotypic background and underlying pathology, which
may contribute to prionuria and prionsialia. Concurrently, we
have begun to explore the tissue origins and protease sensitivity of
the infectious prions as well as the onset and duration of shedding
in these bodily fluids.
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